Immunohematology Billing Services
Where Immunology Meets Hematology, Billing Complexity Doubles. So Does the Revenue Risk.
Immunohematology sits at the exact crossroads of two of medicine's most demanding billing environments. Antibody panels, flow cytometry, biologic infusions, bone marrow diagnostics, and multi-system lab work all landing on the same claim each governed by its own set of rules that most billing teams were never built to handle at the same time. When a single infusion encounter involves a biologic J-code worth $5,000, a concurrent flow cytometry panel, and a set of immunoassays supporting medical necessity the number of ways to lose revenue isn't small. And unlike most specialties, the losses here are rarely small either.
Measurable Revenue Outcomes for Hepatology Practices
.png)
< 30
97%
12–18%
99%
98%
Average Days in AR
Collection Ratios
Revenue Improvement
First Pass Ratio
Clean Claims Accuracy
Full-Cycle RCM
Our Immunohematology Billing Services Every Stage, Every Code, Every Claim
We manage your entire revenue cycle with the coding precision and compliance discipline that immunohematology demands. Nothing gets submitted by assumption, nothing gets written off without a proper appeal, and nothing gets missed because it crossed a specialty boundary.
Eligibility Verification & Prior Authorization Management
Before any biologic infusion or high-cost diagnostic panel, we verify active coverage, confirm Medicare Part B drug benefit availability, and manage the complete PA workflow initial submission, clinical documentation support, PA renewals, and payer-specific medical necessity criteria for every immunotherapy drug in your practice's formulary. We track every active authorization in real time so your treatments are never delivered into a coverage gap.
Precision Immunohematology Coding
Our AAPC certified coders handle the complete immunohematology coding framework flow cytometry marker differentiation across the 86355–86361 series, antibody panel coding, infusion administration hierarchy, J-code dosage unit calculation with NDC attachment, bone marrow procedure and specimen coding, and ICD-10 specificity for multi-system conditions. Every claim is built by a coder who understands how immunology and hematology codes interact on the same claim — not two separate coders working in silos.
High-Value Claims Submission
Every claim goes through a structured pre-submission review built specifically for immunohematology: J-code unit verification against administered dose, NDC attachment confirmation, NCCI edit compliance for flow cytometry and lab panels, infusion sequencing accuracy, active PA verification, and diagnosis-to-procedure linkage check. Our 98% first-pass clean claim rate isn't a generic number it reflects a review process designed around the specific denial patterns we've seen across immunology and hematology payers.
Specialized Denial Management & Appeals
Immunohematology denials are among the most technically layered in all of specialty billing often combining clinical arguments about biologic medical necessity with technical arguments about J-code accuracy, flow cytometry bundling policy, or infusion sequencing rules. We build complete appeals addressing the specific denial reason with the right clinical and billing documentation, then follow through the full Medicare redetermination and reconsideration process when necessary.
Priority AR Follow-Up
Individual immunohematology claims particularly biologic drug claims can represent $3,000 to $10,000 of revenue per encounter. How that AR is prioritized directly determines what your monthly collections look like. We rank every aging claim by dollar value, payer behavior, and denial complexity so follow-up is concentrated where the financial return is highest. No high-value biologic claim fades quietly into a write-off because manual prioritization failed to catch it in time.
Service-Line Revenue Analytics & Reporting
Monthly reporting breaks down revenue by service category biologic infusions, flow cytometry, antibody testing, bone marrow evaluations, and E/M visits so you can see exactly where reimbursement is flowing at full value and where denial patterns or undercoding is eroding it. That visibility is the difference between managing your practice's financial performance proactively and only understanding what happened when last month's numbers arrive.
What Makes Us Different from Every Other Billing Company
✔ AI-Driven Billing That Maximizes Every Claim
✔HImmunohematology Is Our Core Specialty — Not an Add-On
✔ AAPC Certified with Active Specialty Training
✔ Significantly Reduced Days in AR
✔ Complete Visibility Into Every High-Value Claim
✔ One Dedicated Account Manager for Your Practice
✔ Seamless EHR & Practice Management Integration
Six Ways Immunohematology Practices Lose Revenue Every Month Without Knowing It
Flow cytometry billing under the 86355–86361 series requires individual codes for each analyte or cell marker being analyzed. When a ten-marker lymphocyte subset panel gets collapsed into one or two codes instead of being properly broken out, the reimbursement is a fraction of what those panels actually justify. This is one of the most consistently underbilled service categories in immunohematology — not because practices don't run the panels, but because billing teams don't understand how to expand them correctly under NCCI editing rules. It's silent revenue loss that compounds across every panel run.
J-Code Biologic Claims With Wrong Units or Missing NDCs
Rituximab (J9312), IVIG (J1459 or J1460 depending on the specific product and concentration), eculizumab (J1301), and other high-cost biologic agents used in immunohematology must be billed by exact dosage units that match what was administered, with the correct product-specific NDC number attached. When billing teams round dosage units incorrectly, select the wrong J-code for a product's concentration, or submit without the NDC, payers either deny the full claim or reimburse at an incorrect rate. On a drug administered in high doses, that calculation error isn't a minor billing slip — it's a per-session loss that repeats across every treatment cycle.
Prior Authorization Gaps on High-Cost Immunotherapies
IVIG therapy, complement pathway inhibitors, and monoclonal antibodies used in conditions like warm autoimmune hemolytic anemia, ITP, or paroxysmal nocturnal hemoglobinuria all require prior authorizations that must be renewed continuously across treatment cycles. When PA renewals lapse without anyone flagging them, when the ICD-10 diagnosis submitted for authorization doesn't precisely match the code on the claim, or when the supporting lab values in the PA submission are outdated — the claim gets denied after the treatment has already been delivered. Recovering those denials retroactively is difficult and time-consuming. Preventing them with real-time PA tracking is far better for everyone.
Antibody Testing Denied for Medical Necessity Documentation
Antibody identification panels, direct antiglobulin tests, and red blood cell antibody screens are billable services but they carry specific Medicare LCD coverage indications that require explicit clinical documentation linking the testing to a covered ICD-10 diagnosis. When that linkage is absent or too vague, or when repeat testing isn't supported by documentation of the clinical rationale for the testing frequency, payers deny the labs as medically unnecessary. In a specialty where antibody monitoring is a standard part of ongoing disease management, these denials are frequent and avoidable. They're also cumulative across a busy immunohematology panel, they add up fast.
Infusion Sequencing Errors That Silently Reduce Reimbursement
When a patient receives multiple infusions in one session a primary biologic alongside premedication with a corticosteroid or antihistamine the infusion billing hierarchy determines exactly which administration code goes first, which drugs are coded as concurrent add-ons under 96368, and which sequential drugs use 96367. Getting that sequencing wrong doesn't always trigger an obvious denial. It often triggers automated payer bundling edits that quietly reduce the reimbursement without generating a denial that anyone in the billing department notices. These silent underpayments happen across every multi-drug infusion session and are only discovered when someone specifically audits infusion billing patterns against expected reimbursement.
Bone Marrow Diagnostics Billed Incomplete
When a bone marrow biopsy is performed alongside aspiration, the correct code depends on what was actually done and how it's documented either the combined 38222 code, or separate codes for each component based on the procedural record. Beyond the procedure itself, cytogenetics, FISH studies, and flow cytometry performed on the bone marrow specimen are separately billable laboratory services. When billing teams bundle everything under the procedure code or miss the lab and pathology analysis components entirely, the revenue loss per bone marrow evaluation episode is significant and practices that perform these regularly are losing it every time.
MedCloudMD AI — Built to Catch What Manual Review Misses
Our proprietary AI platform works across your entire immunohematology revenue cycle validating J-code calculations, flagging prior authorization gaps before they become denials, and prioritizing high-value claims for follow-up automatically. It's not generic billing software. It was designed specifically for the complexity this specialty creates.
Prior Authorization Lifecycle Monitoring
MedCloudMD AI monitors every active prior authorization across your patient population tracking expiration dates, issuing renewal alerts well ahead of deadlines, and flagging cases where the diagnosis code used to obtain the PA doesn't match the current ICD-10 on the claim. No treatment should go uncompensated because a PA lapsed quietly while your clinical team was focused on patient care.
J-Code Drug Unit Validation
For every biologic drug claim, MedCloudMD AI validates the dosage unit calculation against the documented administered quantity, confirms the correct J-code for the specific product and concentration, and verifies NDC attachment. For high-cost drugs where a unit error means thousands of dollars per session, this validation step alone protects revenue that manual billing review consistently misses at high claim volumes.
Predictive Denial Prevention
MedCloudMD AI cross-references every immunohematology claim against current Medicare LCD policies, NCCI editing rules for flow cytometry, payer-specific J-code coverage criteria, and prior authorization status before a single claim leaves our system. Claims flagged for denial risk are corrected internally stopping the most expensive denial patterns before the payer ever sees them.
Revenue Forecasting by Service Line
MedCloudMD AI generates forward-looking revenue projections broken down by service category biologic infusions, flow cytometry, antibody testing, bone marrow, E/M based on current patient volume, payer mix, and claim approval patterns. That visibility lets you manage the practice's financial performance proactively, not reactively when last month's numbers finally come in.
Smart AR Follow-Up Prioritization
MedCloudMD AI ranks your aging immunohematology claims by dollar value, payer behavior history, and denial complexity so biologic drug claims worth $5,000 or more don't sit in a queue behind lower-value lab denials. High-value claims get immediate follow-up attention, appeal windows don't close unworked, and collections accurately reflect what your practice actually delivered to patients.
Flow Cytometry Panel Optimization
MedCloudMD AI analyzes every flow cytometry order against NCCI editing rules and LCD coverage requirements to ensure each marker is billed under the correct code, the number of separately billable analytes reflects what was actually performed, and the medical necessity documentation linking the panel to the active diagnosis is complete. Underbilled panels are corrected before submission not discovered three months later during a revenue review.
Immunohematology Isn't Two Specialties Bolted Together It's an Entirely Different Billing Ecosystem
Think about what a typical immunohematology patient encounter actually involves. You're managing warm autoimmune hemolytic anemia, so there's a direct antiglobulin test and a red blood cell antibody identification panel both carrying their own CPT codes with Medicare LCD coverage requirements. The patient is on rituximab, so you're billing J9312 by weight-based dosage units with NDC number attachment. A flow cytometry panel is running concurrently to monitor lymphocyte subsets. And the physician is documenting a high-complexity E/M visit. That's four separate billing disciplines on one encounter each with rules the others don't share.
Most billing teams are trained to handle one of those frameworks competently. A handful can manage two. Very few have the depth to manage all of them simultaneously without making errors that cost real money. And in this specialty, those errors are particularly expensive because the individual claim values are exceptionally high. A unit calculation mistake on a biologic drug doesn't cost you $40 it can cost you $3,000 to $6,000 per infusion session, silently, until someone runs an audit that surfaces the pattern.
What makes immunohematology billing genuinely difficult to manage well is that the payer rules governing each component aren't consistent. Medicare's IVIG coverage criteria differ from its flow cytometry LCD requirements. Those LCD requirements vary by MAC jurisdiction. Commercial payer policies for biologic prior authorization change annually and vary by plan. Managing that simultaneously, across a mixed patient population, is exactly the kind of specialized work that general billing teams can't sustain without specialty-specific training and tools built for this environment specifically.
Multi-System Billing in Every Encounter
Immunology codes, hematology lab panels, infusion administration codes, and J-code biologics routinely appear on the same claim each governed by separate coverage criteria, modifier rules, and NCCI bundling restrictions that must all be applied correctly at the same time.
Biologic drugs like rituximab, IVIG, and complement inhibitors carry enormous per-claim values. A single unit miscalculation or missing NDC number can deny thousands of dollars in otherwise legitimate revenue and it can happen across every infusion session before the pattern is detected.
High-Cost Drug Claims at Constant Risk
High-cost immunotherapy biologics require prior authorizations that are among the most documentation-intensive in medicine specific lab value thresholds, treatment history requirements, step therapy compliance, and diagnosis documentation that varies by payer and drug. One lapse stops the reimbursement cold.
Prior Authorization at Every Turn
Flow cytometry panels, antibody identification studies, and bone marrow diagnostics all require clinical documentation that explicitly supports the test type, the specific markers analyzed, and the medical necessity linking each service to an active, covered diagnosis. Payers review this closely and they deny when it's vague.
Documentation Standards That Don't Bend
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
Your Practice Is Processing Complex, High-Value Claims Every Day Every One of Them Should Be Paid at Full Value
Flow cytometry panels billed below their actual value. J-code unit errors costing thousands per infusion. Prior authorization gaps that surface after the treatment is already delivered. These aren't future billing risks they're happening inside your practice right now. Our free immunohematology billing audit identifies every gap with a specific dollar value attached, so you know exactly what you're working with before making any decision.
Frequently asked questions
- 01
- 02
- 03
- 04
- 05
- 06